Clinical Trials · us
Fewer Injections Still Fall Short on Vision: DURAVYU Fails Second Wet AMD Trial
The long-acting intravitreal therapy reduced injections but again failed to demonstrate noninferior vision outcomes versus the comparator. EyePoint will end two wet AMD trials early, cut approximately 53% of its workforce, and shift resources to diabetic macular edema.
Reducing intravitreal injections is an important goal for long-acting retinal therapies, but convenience must be supported by adequate vision outcomes. EyePoint announced on October 19 that its investigational therapy DURAVYU failed to meet the primary endpoint in LUCIA, its second Phase 3 trial in wet age-related macular degeneration. Following the failure of the full data analysis from another pivotal trial, LUGANO, the result prompted the company to reduce its workforce and shift its development focus to diabetic macular edema.
DURAVYU is a sustained-release intravitreal insert containing the tyrosine kinase inhibitor vorolanib, designed to extend treatment intervals through continuous drug delivery. LUCIA enrolled 475 patients and compared DURAVYU administered every 24 weeks with aflibercept injected every 8 weeks; both groups could receive supplemental injections as needed based on their condition. The trial's central question was whether vision outcomes could remain within a prespecified acceptable margin despite less frequent dosing.
According to trial data summarized by Modern Retina, best-corrected visual acuity at the combined assessment of weeks 52 and 56 improved by an average of 2.5 eye chart letters in the DURAVYU group and 6.1 letters in the aflibercept group; the reported between-group difference was minus 3.7 letters. Determining noninferiority requires more than this average difference: the confidence interval must also meet the criteria. In this trial, the confidence interval crossed the prespecified margin of minus 4.5 letters, so noninferiority was not demonstrated. Improvement in both groups was insufficient for the trial to succeed.
The reduction in injections offered another perspective. The company reported that treatment burden in LUCIA was 38% lower than in the comparator group. Retinal Physician noted that, through week 56, 52% of treated eyes in the DURAVYU group had received no supplemental injections, while 71% had received zero or one. However, these secondary results cannot replace the primary vision endpoint that was not met. Modern Retina also cautioned that the comparator was aflibercept injected on a fixed every-8-week schedule, rather than a regimen in which intervals are gradually extended based on the patient's condition. The results therefore cannot be used to directly estimate how many fewer injections patients might receive in routine care.
The consecutive setbacks in the two pivotal trials also changed the company's resource allocation. In a restructuring announcement the same day, EyePoint said it would cut approximately 53% of its workforce and end LUGANO and LUCIA early, without completing the originally planned second year of follow-up. The company estimated that these measures would save approximately $30 million annually and result in approximately $9 million in employee severance-related costs. Ending the trials early also means they will not provide the complete two-year follow-up data originally planned.
EyePoint will next concentrate resources on COMO and CAPRI, the Phase 3 trials of DURAVYU for diabetic macular edema, with topline results expected in the fourth quarter of 2027. The setback in wet AMD does not directly determine success or failure in another indication, but whether fewer injections can also preserve vision must still be answered by the respective controlled trials. The LUCIA data released so far remain preliminary, and the company also plans further analyses of the individual and pooled data to assess the future direction of development in wet AMD.